Insiders · RARE

Michael Narachi

Director at Ultragenyx Pharmaceutical Inc. (RARE)

Michael Narachi has filed 6 insider reports with the SEC since June 2021, as director at Ultragenyx Pharmaceutical Inc. (RARE). The latest filing, on May 18, 2026, reports grant or award at Ultragenyx Pharmaceutical Inc. (RARE).

Filings
6
Companies
1
Bought on market
None
Sold on market
None

Companies where Michael Narachi is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Ultragenyx Pharmaceutical Inc. logo
RARE
Ultragenyx Pharmaceutical Inc.
Director40,441$16.48May 18, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Michael Narachi with

Other insiders at the same companies

Questions about Michael Narachi

What is Michael Narachi's role at Ultragenyx Pharmaceutical Inc.?
Michael Narachi reports to the SEC as director at Ultragenyx Pharmaceutical Inc. (RARE), according to the latest filing on May 18, 2026.
How many shares does Michael Narachi own?
After the latest filing that states it, Michael Narachi directly owned 40,441 shares of Ultragenyx Pharmaceutical Inc. (RARE). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Michael Narachi bought or sold stock recently?
No open-market purchases or sales by Michael Narachi are on file. The filings report grant or award.
How do I get alerts when Michael Narachi files?
Follow Michael Narachi on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Michael Narachi (SEC CIK 0001380022). Totals count each trade once, skipping amendments whose original is on file, from Jun 28, 2021 on. View on SEC EDGAR · Get this as JSON